Peer-influenced content. Sources you trust. No registration required. This is HCN.


The New England Journal of Medicine

Perspective: How Should the FDA Evaluate Psychedelic Medicine?

Psychiatry November 14th 2023

Resolving the Paradox of Long-Term Benzodiazepine Treatment: Toward Evidence-Based Practice Guidelines

Psychiatry November 7th 2023

Specialty Pharmacy Continuum

Change to FDA Biosimilar Labeling Guidelines to Have Little Effect on Consumers

Clinical Pharmacology October 30th 2023

Practical Neurology

New Practice Guidelines for Determining Brain Death/Death by Neurologic Criteria Published

Neurology October 24th 2023

ACP Internist

Guidance Offered for Treating Patients Exposed to Xylazine

Emergency Medicine October 18th 2023


USPSTF Releases Recommendation for Screening for Lipid Disorders in Children, Adolescents

Endocrinology, Diabetes, Metabolism October 11th 2023

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form